Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
University of Colorado researchers find that ulcerations could determine the risk of tumor recurrence and influence cancer treatment.
A growing population of people living with advanced or metastatic cancer has raised questions about the unique needs of these individuals.
Here are latest arrivals approved by the Food and Drug Administration.
New targeted therapy delayed disease progression compared with a placebo.
This approval highlights a trend in cancer research, with drugs being designed for small, genetically defined populations of patients.
Clinical trials showed a high response rate, with almost 85% of participants experiencing tumor shrinkage with this targeted drug.
The study findings “have the potential to open up new avenues for therapeutic intervention in this subset of GIST tumors.”
Here’s a list of the approved drugs to treat gastrointestinal stromal tumors (GIST). Click on any of the medications for...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.